New drug psoriasis does well in trials 

| Melissa Leavitt

A new drug targeting a different part of the immune system shows promise in treating psoriasis.

Unlike other drugs on the market, this treatment, termed IMO-8400, zeroes in on toll-like receptors (TLRs), which are proteins that play a key role in activating immune response. Results from a recent clinical trial of IMO-8400 indicate that the medication, a subcutaneous injection, can safely and effectively improve the symptoms of plaque psoriasis.

The 12-week, placebo-controlled trial involved 32 patients with psoriasis. IMO-8400 reduced the severity of psoriatic lesions by 50 percent in nine patients, and as much as 75 percent in four patients, according to Idera Pharmaceuticals, the drug's manufacturer. None of the patients enrolled in the study reported any adverse side effects.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

A dermatologist explains the best strategies to itch and crack less this season.
When David Harrold called the Patient Navigation Center, he found answers to...
NPF spoke with Junko Takeshita, M.D., Ph.D., about her research on psoriasis...
Twice-a-day pill slows progression of joint damage in addition to reducing pain...
NPF went face-to-face with the “fail-first” insurance policy that comes between...
Don't settle for a mediocre relationship with your provider. These...
The American College of Rheumatology Annual Meeting spotlights the latest news...
Clinical trial data shows Taltz can improve quality of life for those with PsA.
Howard Chang has battled psoriasis for 35 years. When he heard about Treat to...